Claims
- 1. A pharmaceutically acceptable di-basic salt of MM 17880 which is at least 75% pure wherein MM 17880 is a di-acidic solid of the molecular formula C.sub.11-14 H.sub.18-23 O.sub.8-11 N.sub.2 S.sub.2 which in the form of a substantially pure di-sodium salt, has the following properties:
- (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum substantially as shown in FIG. 1;
- (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2;
- (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3;
- (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and
- (e) when mixed with ampicillin or amoxycillin it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes.
- 2. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 in the form of an alkali metal salt.
- 3. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 in the form of the sodium, potassium, calcium, magnesium, aluminium or ammonium salt.
- 4. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 in the form of the di-sodium salt.
- 5. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 in the form of the di-potassium salt.
- 6. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 which is at least 85% pure.
- 7. A pharmaceutically acceptable di-basic salt of MM 17880 according to claim 1 which is 90%-100% pure.
- 8. A process for the preparation of a pharmaceutically acceptable di-basic salt of MM 17880, which is at least 75% pure wherein MM 17880 is a di-acidic solid of the molecular formula C.sub.11-14 H.sub.18-23 O.sub.8-11 N.sub.2 S.sub.2 which in the form of a substantially pure di-sodium salt, has the following properties:
- (a) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum substantially as shown in FIG. 1;
- (b) it has a characteristic nuclear magnetic resonance spectrum which when taken in deuterium oxide is substantially as shown in FIG. 2;
- (c) it has a characteristic ultra-violet spectrum which in water has an absorption maximum at about 297 n.m. substantially as shown in FIG. 3;
- (d) it possesses antibacterial activity against certain gram-positive and gram-negative organisms, including strains of Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhimurium, Serratia marcescens and Staphylococcus aureus; and
- (e) when mixed with ampicillin or amoxycillin it synergizes their antibacterial activity against certain bacteria, including strains of Staphylococcus aureus and Klebsiella aerogenes,
- which comprises cultivating an MM 17880 producing strain of Streptomyces olivaceus having the same identifying characteristics as ATCC 31126 in a suitable medium containing an assimilable source of carbon, hydrogen, sulphur and nitrogen until a significant amount of antibiotic activity has been imparted to said medium and recovering the pharmaceutically acceptable di-basic salt of MM 17880 from the culture medium.
- 9. A process according to claim 8 wherein MM 17880 is isolated in the form of a pharmaceutically acceptable di-basic salt by extracting the di-basic salt into an aqueous lower alkanol solvent followed by chromatographic purification.
Priority Claims (1)
Number |
Date |
Country |
Kind |
10914/75 |
Mar 1975 |
GBX |
|
CROSS REFERENCE
This application is a continuation-in-part of U.S. Patent application Ser. No. 664,917 filed Mar. 8, 1976, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3919415 |
Butterworth et al. |
Nov 1975 |
|
3950357 |
Kattan et al. |
Apr 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
664917 |
Mar 1976 |
|